Parkinson's Disease Trial, Recruiting NCT07306104 Sponsor: University of Southern Denmark Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT07306104
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Intervention Group (active treatment):

  • People who have been diagnosed with idiopathic Parkinson's disease (a specific type of Parkinson's with no known cause)
  • People who are able to understand, agree to, and complete all planned study procedures
  • People whose Parkinson's symptoms, while on their regular medication, fall within stage 1 or 2 on a standard disease severity scale called Hoehn & Yahr (meaning relatively mild symptoms)
  • People who score above 22 on a standard memory and thinking test called the Mini Mental-State Examination

Control Group with Parkinson's Disease:

  • People who have been diagnosed with idiopathic Parkinson's disease
  • People who are able to understand, agree to, and complete all planned study procedures
  • People whose Parkinson's symptoms, while on their regular medication, fall within stage 1 or 2 on the Hoehn & Yahr scale
  • People who score above 22 on the Mini Mental-State Examination

Healthy Reference Group:

  • People who are able to understand, agree to, and complete all planned study procedures

Who may not be able to join:

Intervention Group (active treatment):

  • People who have cancer in the brain, neck, or head area
  • People who have active medical implants (such as a pacemaker) inside their body
  • People who have epilepsy
  • People with alcoholism
  • People with a history of substance abuse
  • People who have an open wound on their scalp
  • People with severe psychiatric or psychological disorders
  • People who are pregnant
  • People whose Parkinson's medication has been changed in the six weeks before the treatment is due to start
  • People currently taking certain blood-thinning medications, including Marevan, Marcoumar, Pradaxa, Eliquis, Xarelto, Lixiana, Novostan, Fragmin, or Innohep
  • People who have a neurological condition other than Parkinson's disease
  • People who have previously had a stroke
  • People whose movement or motor difficulties are caused by something other than Parkinson's disease

Control Group with Parkinson's Disease:

  • People who have a neurological condition other than Parkinson's disease
  • People whose movement or motor difficulties are caused by something other than Parkinson's disease

Healthy Reference Group:

  • People who have any neurological condition
  • People who have reduced movement or motor difficulties caused by any condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anne Sofie Bøgh Malling, Ph.d., University of Southern Denmark

Phone: +45 28903733

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Southern Denmark
Registry
ClinicalTrials.gov
Start date
16 February 2026
Est. completion
1 January 2028

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Sit-to-stand

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov